There are 2867 resources available
1060P - Impact of baseline clinicopathologic and genomic features on outcomes to KRAS G12C inhibitors in patients with NSCLC
Presenter: Giuseppe Lamberti
Session: Poster session 15
1403P - Efficacy and safety of dendrimer-enhanced (DEP) cabazitaxel (CTX-SPL9111) in men with metastatic castration-resistant prostate cancer (mCRPC) in a phase I/II trial
Presenter: Robert Jones
Session: Poster session 11
311P - Differences in stromal component of chordoma are associated with contrast enhancement in MRI and differential gene expression in RNA sequencing
Presenter: Yoon Jin Cha
Session: Poster session 03
1061P - Static and dynamic tracking of radiomic and immunophenotypic features predicts the benefit of immune checkpoint inhibitors in advanced NSCLC
Presenter: Giulia Mazzaschi
Session: Poster session 15
1404P - A phase II study of ZEN-3694 (ZEN), enzalutamide (ENZ), and pembrolizumab (P) in metastatic castration resistant prostate cancer (mCRPC): Interim safety results
Presenter: Tanya Jindal
Session: Poster session 11
312TiP - Impact of early palliative care integration on quality of life and symptom burden in patients with high-grade glioma
Presenter: Joana Reis
Session: Poster session 03
1062P - Predictive impact of inflammation scores in non-small cell lung cancer patients treated with immunotherapy rechallenge
Presenter: Caroline Plazy
Session: Poster session 15
1405P - Circulating tumor DNA in advanced prostate cancer: Focus on high blood tumor mutational burden (h-bTMB)
Presenter: Zoé Guillaume
Session: Poster session 11
313TiP - Phase II study on the safety and efficacy of fluzoparib and temozolomide in primary glioblastoma
Presenter: Hongfei Zhang
Session: Poster session 03
1063P - Comprehensive genomic profiling of leptomeningeal metastases on NSCLC patients through circulating tumor DNA in cerebrospinal fluid
Presenter: Yang Sen
Session: Poster session 15